Fennec Pharmaceuticals Inc. (FENC)
- Previous Close
4.5200 - Open
4.5800 - Bid 4.6000 x 100
- Ask 4.6400 x 200
- Day's Range
4.5500 - 4.7000 - 52 Week Range
4.5000 - 11.9200 - Volume
64,556 - Avg. Volume
85,790 - Market Cap (intraday)
126.425M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
66.00 - EPS (TTM)
0.0700 - Earnings Date Nov 4, 2024 - Nov 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.50
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
www.fennecpharma.comRecent News: FENC
View MorePerformance Overview: FENC
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FENC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FENC
View MoreValuation Measures
Market Cap
126.43M
Enterprise Value
115.16M
Trailing P/E
66.00
Forward P/E
10.35
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.69
Price/Book (mrq)
57.93
Enterprise Value/Revenue
2.36
Enterprise Value/EBITDA
17.49
Financial Highlights
Profitability and Income Statement
Profit Margin
5.59%
Return on Assets (ttm)
8.88%
Return on Equity (ttm)
--
Revenue (ttm)
48.89M
Net Income Avi to Common (ttm)
2.73M
Diluted EPS (ttm)
0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
43.05M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.87M